Figure 1.

Individual patient sampling model. In the lifetime simulation, each patient is either assigned to the VN group or to the SoC group. During each cycle, BCVA and VF are tracked and direct and indirect costs are assessed. Even in the treatment group, patients can eventually be subject to natural progression depending on the model's assumption toward treatment effect duration. QALYs are recorded and ICURs calculated.